BeiGene Ltd (FRA:49BA)
€ 152 5 (3.4%) Market Cap: 15.89 Bil Enterprise Value: 14.29 Bil PE Ratio: 0 PB Ratio: 5.18 GF Score: 69/100

Beigene Ltd at Barclays Global Healthcare Conference Transcript

Mar 13, 2019 / 07:20PM GMT
Release Date Price: €121.58 (+0.48%)
Gena Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon, everyone. My name is Gena Wang. I'm the SME-cap biotech analyst. It's my great pleasure to introduce our next speaker, Howard Liang, Chief Financial and Strategy Officer of BeiGene.

Heng Liang
BeiGene, Ltd. - CFO & Chief Strategy Officer

Thanks so much, Gena. It's great to be presenting, give you an update of BeiGene. Before I start, I need to remind you that I'll be making forward-looking statements, and our business carries risk.

So I'll start by giving a overview of BeiGene by telling you our overall strategy in building a leading global biotech company from China. We -- there are 4 parts of our near-term and intermediate-term strategy. First is to focus on our 2 near-term product opportunities with a BTK inhibitor as a global potentially best-in-class drug that we develop globally as well as a PD-1 antibody that is developed to address the large opportunities in China, Asia and beyond.

Second, we've been very focused on developing our strategic

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot